R. Michael Gendreau
2021
In 2021, R. Michael Gendreau earned a total compensation of $688.3K as Chief Medical Officer at Virios Therapeutics, a 2,194% increase compared to previous year.
Compensation breakdown
Non-Equity Incentive Plan | $113,750 |
---|---|
Option Awards | $228,412 |
Salary | $325,000 |
Other | $21,151 |
Total | $688,313 |
Gendreau received $325K in salary, accounting for 47% of the total pay in 2021.
Gendreau also received $113.8K in non-equity incentive plan, $228.4K in option awards and $21.2K in other compensation.
Rankings
In 2021, R. Michael Gendreau's compensation ranked 9,951st out of 12,406 executives tracked by ExecPay. In other words, Gendreau earned more than 19.8% of executives.
Classification | Ranking | Percentile |
---|---|---|
All | 9,951 | 20th |
Manufacturing | 4,399 | 20th |
Chemicals And Allied Products | 1,955 | 17th |
Drugs | 1,737 | 17th |
Pharmaceutical Preparations | 1,291 | 16th |
Gendreau's colleagues
We found three more compensation records of executives who worked with R. Michael Gendreau at Virios Therapeutics in 2021.
News
Virios Therapeutics CEO Greg Duncan's 2023 pay falls 39% to $567K
April 25, 2024
Virios Therapeutics CEO Greg Duncan's 2022 pay slips 15% to $937K
April 27, 2023
Virios Therapeutics CEO Greg Duncan's 2021 pay falls 69% to $1.1M
April 26, 2022
Virios Therapeutics CEO Greg Duncan receives $3.5M in 2020
April 28, 2021